Myeloma & Cell Therapy WORKSHOP October 14-15, 2021 OSTRAVA Bright talks for outstanding research Partners Organized by Organization committee University of Ostrava Blood Cancer Research Group Cell Coolab Ostrava University Hospital Ostrava Michal Šimíček, Ph.D. Hana Šahinbegović Renata Šnaurová Sandra Charvátová Marcello Turi XVI. Myeloma and IV.Cell Therapy Workshop 2021 OSTRAVA Welcome to for the
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Myeloma & Cell TherapyWORKSHOP
October 14-15, 2021
OSTRAVA
Bright talks for outstanding research
Partners
Organized by Organization committeeUniversity of OstravaBlood Cancer Research GroupCell Coolab Ostrava
University Hospital Ostrava
Michal Šimíček, Ph.D.Hana Šahinbegović
Renata ŠnaurováSandra Charvátová
Marcello Turi
XVI. Myeloma and IV.Cell Therapy Workshop 2021 OSTRAVAWelcome to for the
10:10
10:35
11:15
11:40
12:05
13:30
13:55
14:20
14:45
09:45
14 Oct 2021
OSTRAVAOctober 14-15, 2021
9:30
Closing remarks for the day
Coffee break
Lunch break
SOCIAL EVENT at “Hola bar & tapas”
9:45 SESSION I
11:15 SESSION II
Opening remarks - Roman Hájek and Michal Šimiček
Characterization of multiple myeloma by an integrative geno-transcriptomic approach:from the genomic architecture to its functional consequences Da Via' Matteo Claudio, University of Milan, Italy
New applications of next-generation flow cytometry in multiple myeloma Bruno Paiva, Center for Applied Medical Research, Spain
Next generation proteomics with drug sensitivity screening identifies sub-clonesinforming therapeutic and drug development strategies for multiple myeloma patients Despina Bazou, Mater Misericordiae University Hospital, Ireland
Microenvironment dysregulation in multiple myeloma: novel challengesand therapeutic opportunitiesCirino Botta, University of Palermo, Italy
Exosomes as key mediators in BM-MM crosstalk Eline Menu, VUB Brussels, Belgium
Stromal cell-centric bone marrow inflammation in multiple myelomaTom Cupedo, Erasmus MC Rotterdam, The Netherlands
13:30 SESSION IIIPathogenesis of extramedullary multiple myeloma: from resistance to identificationTereza Sevcikova, Blood Cancer Research Group, Czech Republic
New Immunotherapy targets in multiple myeloma clinical dataLuciano Costa - University of Alabama at Birmingham
Multiple myeloma genomic defining eventsFrancesco Maura, Sylvester Comprehensive Cancer Center, University of Miami, USA “Multiple myeloma genomic defining events”
Diagnosis, prognosis and therapy of immunoglobulin light chain amyloidosisMorie Gertz, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
XVI. Myeloma and IV.Cell Therapy Workshop 2021
09:55
10:20
11:15
11:50
12:15
14:00
14:30
14:55
15:20
09:30
15 Oct 2021
12:40
OSTRAVAOctober 14-15, 2021
Closing remarks
Coffee break
Lunch break
11:15 SESSION VNew targets and technologies for CAR-T cell therapy Michael Hudecek, University of Würzburg, Germany
NK cells immunotherapy in multiple myelomaMonika Holubová, Fakultní nemocnice Plzeň, , Czech Republic
Delineating tumor heterogeneity in the era of novel immunotherapies in multiple myelomaLeo Rasche, Universty of Würzburg, Germany
Alternative RNA processing prospective RNA toolkit in myeloma cell therapySophia Adamia, Dana-Farber Cancer Institute, USA
14:00 SPECIAL SESSIONNew Therapies in MyelomaKenneth Anderson, Dana-Farber Cancer Institute, USA
9:30 SESSION IVFunctional precision medicine for biomarker discovery and treatment support of relapsed/refractory myeloma patients Caroline Heckman, Institute for Molecular Medicine Finland, Finland
Circulating plasma cells as critical diagnostic marker in the newly diagnosed multiple myelomaTomas Jelinek, Blood Cancer Research Group, Ostrava, Czech Republic
Connection between autophagy and oncogenic MyD88 signalingMarcello Turi, Blood Cancer Research Group, Czech Republic
CD19 promotor hypermethylation results in CD19 antigen-negative relapse to CAR-T cellsMichal Smida, Citec, Czech Republic
Allogenic CAR-T cellsPiotr Celichowski, Blood Cancer Research Group, Ostrava, Czech Republic
The role of NK cells in treatment of multiple myelomaMichael O'Dwyer, National University of Ireland, Ireland